Tsifran od Tab n / a film about prolong. 1000mg 10 pieces

$6.75

Tsifran od Tab n / a film about prolong. 1000mg 10 pieces

Quantity:

Description

Composition
Active substance:
1 tablet sustained release film coating comprises: ciprofloxacin – 1000 mg.
Excipients:
Sodium alginate (Keltone LVCR), hypromellose, sodium bicarbonate, crospovidone (CLM), magnesium stearate, colloidal silicon dioxide (200), talc. Film coating: Opadry White 31V58910 *, talc, hypromellose, purified water, the ink for black lettering (Opakod-S-l-17823 Black). * Opadry White 31V58910 composition: hypromellose, lactose, titanium dioxide, Macrogol 400; ** evaporated during the manufacturing process *** it is composed of: 45% shellac (20% esterified) in ethanol, isopropanol, n-butanol, propilenglyukol, 28% aqueous ammonia, iron oxide black dye.
Description:
Tablets oval, white to off-white, film-coated, on one side of the tablet edible ink printed Cifran OD 1000 mg.
Product form:
Prolonged action tablets, film-coated 500 mg, 1000 mg. 5 tablets per blister consisting of aluminum foil on one side and aluminum foil coated with the polyamide film and the PVC film on the other side; 1 or 2 in the blister cardboard pack with instructions for use.
Contraindications
Pseudomembranous colitis, age 18 years, pregnancy, lactation, increased susceptibility to ciprofloxacin or other drugs of fluoroquinolone, simultaneous tizanidine (risk of significant decrease in blood pressure, drowsiness), chronic renal failure (creatinine clearance less than 29 mL / min, including patients on hemodialysis).
Precautions: pronounced cerebral atherosclerosis; cerebrovascular accident; psychiatric diseases, epilepsy, renal failure (creatinine clearance of 35-50 ml / min) expressed by liver failure, advanced age, tendon lesion at the previously held treatment fluoroquinolones.
Dosage
1 g
Indications
TSifran OD indicated for the treatment of the following infectious and inflammatory diseases caused by susceptible microorganisms. Acute sinusitis, infectious and inflammatory diseases of the lower respiratory tract, including pneumonia, exacerbation of chronic bronchitis and cystic fibrosis infectious complications, pyelonephritis, cystitis (including complications), chronic bacterial prostatitis, gonorrhea, intra-abdominal infections (including peritonitis, intra-abdominal abscess, cholangitis, cholecystitis, empyema of the gall bladder) is used in combination with metronidazole, infectious diseases of the skin, infectious diseases, bone and joints (including acute and chronic osteomyelitis um), diarrhea, infectious genesis – including “Travelers’ diarrhea”, typhoid, anthrax.
Interaction with other drugs
Because inhibition of microsomal enzymes in the liver, improves concentration and lengthens T1 / 2 of theophylline and other xanthines (e.g. caffeine), oral hypoglycemic drugs (e.g. glibenclamide), anticoagulants (e.g., warfarin and its derivatives). If necessary, concomitant use with preparations of these groups need to control drug concentration in the blood and adjust the dosing regimen. In the presence of antacid preparations containing magnesium hydroxide or aluminum hydroxide is reduced absorption of ciprofloxacin. Thus, simultaneous reception of these drugs should be avoided. In such cases, ciprofloxacin should take 1-2 hours either before or after 4 hours after taking these drugs. Didanosine reduces the absorption of ciprofloxacin. This is due to the formation of complexes with magnesium salts contained in preparations of didanosine. When combined with probenecid, etc. Blocking drugs tubular secretion decreases renal excretion of ciprofloxacin. Metoclopramide accelerates the absorption of the drug, which reduces the time required to reach its Cmax. Co-administration of uricosuric drugs leads to excretion slowdown (50%) and increase plasma concentration of ciprofloxacin.
When combined with other antimicrobial drugs (beta-lactam antibiotics, aminoglycosides, clindamycin, metronidazole) commonly observed synergism; It can be used successfully in combination with ceftazidime and azlocillin in infections caused by Pseudomonas spp .; with mezlocillin, azlocillin and other beta-lactam antibiotics – in streptococcal infections; with izoksazolilpenitsillinami and vancomycin – with staphylococcal infections; metronidazole and clindamycin – In anaerobic infections.
Ciprofloxacin amplifies nephrotoxic effect of cyclosporine. Marked increase in serum creatinine concentration. These patients should be monitored this indicator 2 times a week. The simultaneous use of tizanidine with ciprofloxacin which is an inhibitor of CYP1A2 isoenzyme, causes a 10-fold increase in AUC of tizanidine. The result of the combined application may be clinically significant and sustained reduction in blood pressure, leading to drowsiness, dizziness, confusion psychomotor reactions. In patients receiving therapy with ciprofloxacin and phenytoin, marked variation (decrease or increase) the concentration of phenytoin in blood plasma. The combined use of nonsteroidal anti-inflammatory drugs (NSAIDs) increases the likelihood of side effects of ciprofloxacin on the part of the central nervous system (risk of seizures). Absorption ciprofloxacin the oral route, reduced after cytotoxic anticancer therapy and immunosuppressive drugs.
Overdose
Perhaps reversible renal toxicity; There is no specific antidote, so you need to induce vomiting or to gastric lavage and symptomatic therapy: to carry out measures for adequate hydration (fluid therapy); maintenance therapy. Only minor amounts of ciprofloxacin (
pharmachologic effect
Pharmacological group:
The antimicrobial agent – fluoroquinolone.
Pharmacodynamics:
The bactericidal effect caused by inhibition of fluoroquinolones bacterial enzyme – topoisomerase II (DNA gyrase). Topoisomerase II is necessary for normal replication of bacterial DNA. This ATP-dependent process in the absence of topoisomerase II leads to uncontrolled replication of damaged DNA and hence to the disruption of normal protein synthesis in the bacterial cell. Ciprofloxacin possesses pronounced activity in vitro against a broad spectrum of gram-negative and gram-positive bacteria. Ciprofloxacin acts as breeding microorganisms, and on which are at rest. As revealed in vitro studies and the applications in clinical studies, ciprofloxacin active against most strains of microorganisms: Gram-positive (Bacillus anthracis, Enterococcus faecalis (strains most relatively sensitive), Lysteria monocytogenes, Staphylococcus epidermidis, Staphylococcus saprophyticus). Staphylococcus aureus (methicillin – susceptible and producing penicillinase, methicillin partially – resistant strains), Streptococcus pneumoniae, Streptococcus pyogenes; aerobic gram (Campylobacter jejuni, Citrobacter diversus, Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Haemophilus parainfluehzae, Klebsiella pneumoniae, Moraxella catarrhalis, Morganella morganii, Neisseria gonorrhoeae, Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, Pseudomonas aeruginosa, Salmonella typhi , Serratia marcescens, Shigella boydii, Shigella dysenteriae, Shigella flexneri, Shigella sonnei). In in vitro studies of ciprofloxacin in the minimum inhibitory concentration (MIC) of 90%) following strains of microorganisms, but the clinical relevance of these data has specified. Aerobic Gram-positive: Staphylococcus haemolyticus, Staphylococcus hominis, Streptococcus pneumoniae. Aerobic gram-negative: Acinetobacter lwoffii, Aeromonas hydrophilia, Edwardsiella tarda, Klebsiella oxytoca, Legionella pneumophila, Salmonella enteritidis, Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificus, Yersinia enterocolitica. Other microorganisms: Mycobacterium tuberculosis (relatively sensitive). Most strains Burkholderia cepacia, and Stenotrophomonas maltophilia some strains resistant to ciprofloxacin, like most anaerobic bacteria including Bacteroides fragilis and Clostridium difficile.
Pharmacokinetics:
Pharmacokinetics: absorption: after oral administration ciprofloxacin is quickly absorbed from the gastrointestinal tract. Tsifran® OD tablets provide sustained, uniform release of ciprofloxacin, the drug is taken once a day. One dose Tsifran® OD 500 mg and 1000 mg OD Tsifran® able to maintain the necessary concentration of ciprofloxacin, which in other cases is provided by a conventional double ciprofloxacin 250 mg or 500 mg, respectively: allocation: after administration of a single dose maximum plasma concentration (Cmax) achieved in for 6 hours and up 1.3 ± 0.4 mcg / mL and 2.4 ± 0.7 mcg / mL for 500 mg Tsifran® OD OD Tsifran® and 1000 mg respectively. The corresponding values ​​of area under the concentration-time curve (AUC0-t) 83 ± 2.1 and 18.9 ± 4.6 ug * mL / hr. Binding to plasma proteins from 20% to 40%. Ciprofloxacin is a well penetrates the tissues and body fluids: lungs, skin, adipose tissue, muscles, cartilage and bone tissue, prostate gland, in the saliva secretion of mucous membranes of the nasal cavity and bronchial tubes, semen, lymph, peritoneal fluid and prostate secretion. Metabolism: ciprofloxacin partially metabolized in the liver. Excretion: about 50% of an oral dose is excreted by the kidneys in unchanged form and about 15% as active metabolites. Approximately 20-35% of the dose released intestine. The half-life (T1 / 2) Tsifran® OD is about 6.5-7.5 hours. T1 / 2 can be extended with severe renal insufficiency and in the elderly. Special patient groups
When compromised renal functions In patients with impaired renal function significantly, the half-life of ciprofloxacin may slightly increase. In this case carrying out correction dosing regimen (see. “Dosage and Administration”). At impaired hepatic function: In a pilot study in patients with stable cirrhosis were observed no significant changes in the pharmacokinetics of ciprofloxacin. However, studies on the kinetics of ciprofloxacin in patients have not been conducted with acute liver failure.
Pregnancy and breast-feeding
Tsifran OD primenenyat during pregnancy is not recommended. Ciprofloxacin is excreted in breast milk, so the lactation period, if you want to use TSifran OD, is based on the extent of its application the importance of the mother should decide whether to discontinue the drug or breast-feeding.
Conditions of supply of pharmacies
Prescription.
side effects
From the digestive system: nausea, vomiting, diarrhea, abdominal pain, flatulence, anorexia, cholestatic jaundice (especially in patients with prior liver disease), hepatitis, gepatonekroz. From the nervous system: dizziness, photophobia, insomnia, paresthesia, irritability, headache, fatigue, anxiety, tremor, “nightmarish” dream, peripheral paralgeziya (anomaly perception of feeling pain), increased intracranial pressure, confusion, depression, hallucinations, as well as others. manifestations of psychotic reactions (sometimes progressing to the states in which the patient may cause harm to themselves), migraine, syncope, cerebral arterial thrombosis. From the senses: taste and smell disturbances, blurred vision (diplopia, changes in color vision), tinnitus, hearing loss. Cardio-vascular system: tachycardia, cardiac arrhythmia, lower blood pressure, “tides” of blood to the skin. On the part of the hematopoietic system: eosinophilia, leukopenia, granulocytopenia, anemia, thrombocytopenia, leukocytosis, thrombocytosis, haemolytic anemia. Laboratory findings: hypoprothrombinemia, increased activity of “liver” transaminases, hypercreatininemia, hyperbilirubinemia, hyperglycemia, elevated alkaline phosphatase, and lactate dehydrogenase.
From the mochevydelitelnoy system: hematuria, crystalluria (especially at alkaline urine and low diuresis), acute interstitial nephritis (with the possible development of acute renal failure), glomerulonephritis, dysuria, polyuria, urinary retention, albuminuria, urethral bleeding, reduced azotovydelitelnoy kidney function .
Allergic reactions: itching, hives, blisters, accompanied by bleeding, and the appearance of small nodules that form scabs, drug fever, petechial hemorrhages in the skin (petechiae), swelling of the face or throat, shortness of breath, vasculitis, erythema nodosum, erythema multiforme exudative, malignant erythema multiforme (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome). On the part of the musculoskeletal system: arthralgia, arthritis, tenosynovitis, tendon ruptures, myalgia. Other: increased sweating, photosensitivity, fatigue, superinfection (candidiasis, pseudomembranous colitis).
special instructions
Some patients receiving fluoroquinolones, photosensitivity reactions were observed. Avoid excessive exposure to direct sunlight and UV radiation. In the event of photosensitivity reactions recommended to stop using the product. Since Tsifran® OD drug is possible with reversible toxic effects on the kidneys, its use is not recommended for patients with impaired kidney function, creatinine clearance
During the treatment should refrain from activities potentially hazardous activities that require attention and speed of mental and motor responses.
Storage conditions
In a dry place at a temperature not higher than 25 ° C. Keep out of the reach of children.
Dosing and Administration
Inside. You should not crush, chew, or in any other way to destroy the tablets. Tablets should be taken inside after eating whole, drinking plenty of water. Application of OD TSifran should continue for at least another 2 days after the complete disappearance of symptoms. Recommended dosage for adults.
In acute sinusitis, light / average severity – 1000 mg dose, the frequency of application every 24 hours, duration of treatment 10 days. In infectious and inflammatory diseases of the lower respiratory tract, light / average severity – 1000 mg dose, the frequency of application every 24 hours, the duration of treatment of 7-14 days. In infectious and inflammatory diseases of the lower respiratory tract, severe / complicated severity – 1500 mg dose, the frequency of application every 24 hours, the duration of treatment of 7-14 days. In the urinary tract infection, acute uncomplicated severity – 500 mg dose, the frequency of application every 24 hours, 3 days duration of therapy. In the urinary tract infection, light / average severity – 500 mg dose, the frequency of application every 24 hours, the duration of treatment of 7-14 days. When urinary tract infections, severe / complicated severity – 1000 mg dose, the frequency of application every 24 hours, the duration of treatment of 7-14 days. In chronic bacterial prostatitis, light / average severity – 1000 mg dose, the frequency of application every 24 hours, duration of treatment 28 days. In gonorrhea, acute uncomplicated severity – 500 mg dose, frequency of administration singly, duration of treatment 1 day. In gonorrhea complicated severity – 500 mg dose, the frequency of application every 24 hours, 3-5 days duration of therapy. * When intraabdominal infections, complicated severity – 1000 mg dose, the frequency of application every 24 hours, the duration of treatment of 7-14 days (* used in combination with metronidazole). In infectious diseases of the skin, light / average severity – 1000 mg dose, the frequency of application every 24 hours, the duration of treatment of 7-14 days. In infectious diseases of the skin, severe / complicated severity – 1500 mg dose, the frequency of application every 24 hours, the duration of treatment of 7-14 days. In infectious diseases of bones and joints, light / average severity – 1000 mg dose, the frequency of application every 24 hours, duration of therapy 4-6 weeks. In infectious diseases of bones and joints, severe / complicated severity – 1500 mg dose, the frequency of application every 24 hours, duration of therapy> 4-6 weeks. Diarrhea of ​​infectious origin – including “Travelers diarrhea ‘, light / moderate / severe severity – 1000 mg dose, the frequency of application every 24 hours, 5-7 days duration of therapy. When typhoid, light / average severity – 1000 mg dose, the frequency of application every 24 hours, duration of treatment 10 days. When anthrax – 1000 mg dose, the frequency of application every 24 hours, duration of treatment 60 days. Correction of dosing regimen in patients with renal insufficiency, see. In the manufacturer’s instructions.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Ranbaxy RX

There are no reviews yet.

Add your review